Tilman U. Esser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tilman U. Esser has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Annalise Anspach
Experimental Renal and Cardiovascular Research Department of Nephropathology Institute of Pathology Friedrich‐Alexander‐Universität Erlangen‐Nürnberg (FAU) Muscle Research Center Erlangen (MURCE) 91054 Erlangen Germany
2 shared publications- Ben Fabry
Department of Physics, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany
2 shared publications Dirk W. Schubert
Institute of Polymer Materials Department of Materials Science and Engineering University of Erlangen‐Nuremberg 91058 Erlangen Germany
2 shared publications- Felix Benedikt Engel
Experimental Renal and Cardiovascular Research, Department of Nephropathology, Institute of Pathology and Department of Cardiology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
2 shared publications Joachim Schenk
Rudolf Virchow Center Center for Integrative and Translational Bioimaging Julius‐Maximilians‐Universität Würzburg (JMU) 97080 Würzburg Germany
2 shared publicationsKatrin A. Muenzebrock
Experimental Renal and Cardiovascular Research Department of Nephropathology Institute of Pathology Friedrich‐Alexander‐Universität Erlangen‐Nürnberg (FAU) Muscle Research Center Erlangen (MURCE) 91054 Erlangen Germany
2 shared publications
Latest Publications
- Open Access
- 20 November 2023
- Published by Wiley in Advanced Materials
- Vol. 35 (52) , e2305911
Direct 3D‐Bioprinting of hiPSC‐Derived Cardiomyocytes to Generate Functional Cardiac Tissues
3D‐bioprinting is a promising technology to produce human tissues as drug screening tool or for organ repair. However, direct printing of living cells has proven difficult. Here, a method is presented to directly 3D‐bioprint human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes embedded in a collagen–hyaluronic acid ink, generating centimeter‐sized functional ring‐ and ventricle‐shaped cardiac tissues in an accurate and reproducible manner. The printed tissues contain hiPSC‐derived cardiomyocytes with well‐organized sarcomeres and exhibit spontaneous and regular contractions, which persist for several months and are able to contract against passive resistance. Importantly, beating frequencies of the printed cardiac tissues can be modulated by pharmacological stimulation. This approach opens up new possibilities for generating complex functional cardiac tissues as models for advanced drug screening or as tissue grafts for organ repair or replacement.
- 20 November 2023
- Published by Wiley in Advanced Materials
- Vol. 35 (52) , e2305911
Open AccessDirect 3D‐Bioprinting of hiPSC‐Derived Cardiomyocytes to Generate Functional Cardiac Tissues
3D‐bioprinting is a promising technology to produce human tissues as drug screening tool or for organ repair. However, direct printing of living cells has proven difficult. Here, a method is presented to directly 3D‐bioprint human induced pluripotent stem cell (hiPSC)‐derived cardiomyocytes embedded in a collagen–hyaluronic acid ink, generating centimeter‐sized functional ring‐ and ventricle‐shaped cardiac tissues in an accurate and reproducible manner. The printed tissues contain hiPSC‐derived cardiomyocytes with well‐organized sarcomeres and exhibit spontaneous and regular contractions, which persist for several months and are able to contract against passive resistance. Importantly, beating frequencies of the printed cardiac tissues can be modulated by pharmacological stimulation. This approach opens up new possibilities for generating complex functional cardiac tissues as models for advanced drug screening or as tissue grafts for organ repair or replacement.
- Open Access
Direct 3D-bioprinting of hiPSC-derived cardiomyocytes to generate functional cardiac tissues
3D-bioprinting is a promising technology to produce human tissues as drug screening tool or for organ repair. However, direct printing of living cells has proven difficult. Here, we present a method to directly 3D-bioprint human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes embedded in a collagen-hyaluronic acid ink generating centimeter-sized functional ring- and ventricle-shaped cardiac tissues in an accurate and reproducible manner. The printed tissues contained hiPSC-derived cardiomyocytes with well-organized sarcomeres and exhibited spontaneous and regular contractions, which persisted for several months and were able to contract against passive resistance. Importantly, beating frequencies of the printed cardiac tissues could be modulated by pharmacological stimulation. This approach opens up new possibilities for generating complex functional cardiac tissues as models for advanced drug screening or as tissue grafts for organ repair or replacement.
Open AccessDirect 3D-bioprinting of hiPSC-derived cardiomyocytes to generate functional cardiac tissues
3D-bioprinting is a promising technology to produce human tissues as drug screening tool or for organ repair. However, direct printing of living cells has proven difficult. Here, we present a method to directly 3D-bioprint human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes embedded in a collagen-hyaluronic acid ink generating centimeter-sized functional ring- and ventricle-shaped cardiac tissues in an accurate and reproducible manner. The printed tissues contained hiPSC-derived cardiomyocytes with well-organized sarcomeres and exhibited spontaneous and regular contractions, which persisted for several months and were able to contract against passive resistance. Importantly, beating frequencies of the printed cardiac tissues could be modulated by pharmacological stimulation. This approach opens up new possibilities for generating complex functional cardiac tissues as models for advanced drug screening or as tissue grafts for organ repair or replacement.
- Open Access
- 26 July 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (21) , 3300-3305
Chalcone‐Supported Cardiac Mesoderm Induction in Human Pluripotent Stem Cells for Heart Muscle Engineering
Human pluripotent stem cells (hPSCs) hold great promise for applications in cell therapy and drug screening in the cardiovascular field. Bone morphogenetic protein 4 (BMP4) is key for early cardiac mesoderm induction in hPSC and subsequent cardiomyocyte derivation. Small‐molecular BMP4 mimetics may help to standardize cardiomyocyte derivation from hPSCs. Based on observations that chalcones can stimulate BMP4 signaling pathways, we hypothesized their utility in cardiac mesoderm induction. To test this, we set up a two‐tiered screening strategy, (1) for directed differentiation of hPSCs with commercially available chalcones (4’‐hydroxychalcone [4’HC] and Isoliquiritigen) and 24 newly synthesized chalcone derivatives, and (2) a functional screen to assess the propensity of the obtained cardiomyocytes to self‐organize into contractile engineered human myocardium (EHM). We identified 4’HC, 4‐fluoro‐4’‐methoxychalcone, and 4‐fluoro‐4’‐hydroxychalcone as similarly effective in cardiac mesoderm induction, but only 4’HC as an effective replacement for BMP4 in the derivation of contractile EHM‐forming cardiomyocytes.
- 26 July 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (21) , 3300-3305
Open AccessChalcone‐Supported Cardiac Mesoderm Induction in Human Pluripotent Stem Cells for Heart Muscle Engineering
Human pluripotent stem cells (hPSCs) hold great promise for applications in cell therapy and drug screening in the cardiovascular field. Bone morphogenetic protein 4 (BMP4) is key for early cardiac mesoderm induction in hPSC and subsequent cardiomyocyte derivation. Small‐molecular BMP4 mimetics may help to standardize cardiomyocyte derivation from hPSCs. Based on observations that chalcones can stimulate BMP4 signaling pathways, we hypothesized their utility in cardiac mesoderm induction. To test this, we set up a two‐tiered screening strategy, (1) for directed differentiation of hPSCs with commercially available chalcones (4’‐hydroxychalcone [4’HC] and Isoliquiritigen) and 24 newly synthesized chalcone derivatives, and (2) a functional screen to assess the propensity of the obtained cardiomyocytes to self‐organize into contractile engineered human myocardium (EHM). We identified 4’HC, 4‐fluoro‐4’‐methoxychalcone, and 4‐fluoro‐4’‐hydroxychalcone as similarly effective in cardiac mesoderm induction, but only 4’HC as an effective replacement for BMP4 in the derivation of contractile EHM‐forming cardiomyocytes.